Target_ID_Validation

Target ID & Validation

Target-to-Lead

Lead_to_Candidate

Lead-to-Candidate

Preclincial

Preclinical

Clinical

Clinical

Meet us at SLAS 2024

Feb 3-7, 2024
Booth #587
Boston, MA

Meet us at German Cancer Congress

Feb 21-24, 2024
Booth #D2.5A
Berlin, Germany

Latest News

Celebrating Three Years of Fruitful Collaboration: Nuvisan ICB and Bayer Pharmaceuticals

We value strategic partnerships for scientific advancement, with the goal of pushing scientific boundaries and impacting patients’ lives. Our collaboration will continue to progress.

→ Learn More

Drug Discovery Expertise Fuels Bill & Melinda Gates Foundation Grant

NUVISAN The Science CRO has received a $9.6 million grant from the Bill & Melinda Gates Foundation for breakthrough discovery and early development of new non-hormonal contraceptives.

→ Learn More

2023 EcoVadis Gold Medal: NUVISAN's Sustainability Win

NUVISAN ICB was awarded the 2023 EcoVadis Gold Medal for Sustainability, which highlights our commitment to reducing our carbon footprint and making a positive impact on the community. Thank you to EcoVadis for recognizing our work!

→ Learn More

Explore NUVISAN's Insights

Explore NUVISAN's scientific publications, videos, webinars, and more to gain insights into our solutions and projects, and see how our teams can support your scientific journey.

→ Learn More

Drug Discovery & Development meet Scientific Excellence

The NUVISAN group is a Contract Research and Development & Manufacturing Organization (CRO/CDMO) with six sites in Germany and France as well as local experts situated in Latin America.

We offer unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain to our biotech startup, pharma, non-profit, and venture capital clients – from target identification to the patient.

Thanks to more than 40 years of experience and about 1,000 employees (incl. >70 % industry experienced scientists and lab professionals), we know how to discover, develop, and bring the next generation medicines to market. At the same time, our scientists understand that every project is different. With a flexible and innovative approach and transparent communication, our teams are passionate about closely collaborating with you to adapt to your individual needs.